SHINE Awarded $20.9 million DOE/NNSA Phase II Cooperative Agreement

SHINE Awarded $20.0 Million

December 14th, 2016 | Posted in: Press Release

Janesville, WI – SHINE Medical Technologies, Inc. (SHINE), a Wisconsin-based medical isotope company, announced today that it has been awarded $10 million from the U.S. Department of Energy’s National Nuclear Security Administration (DOE/NNSA) as part of a $20.9 million cooperative agreement. The Phase II funding was awarded through the DOE/NNSA’s molybdenum-99 (moly-99) program, which works to support the establishment of domestic, commercial production of moly-99 produced without the use of highly-enriched uranium.

Share on FacebookTweet about this on TwitterShare on Google+Share on LinkedInEmail this to someonePrint this page
Read More +